NASDAQ · Biotechnology

CRMD (CRMD) Stock

$7.33 +1.88% NASDAQ: CRMD Healthcare

Valuation

MetricValue
Price$7.33
Market Cap$574.66M
P/E Ratio3.94
P/B Ratio1.53
P/S Ratio1.68
EPS (TTM)$0.00
52-Week High$17.43
52-Week Low$6.13
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE65.59%
ROA26.40%
ROCE37.04%
Gross Margin85.83%
Operating Margin48.41%
Net Margin45.25%
Debt/Equity0.33
Current Ratio2.11

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$43.0M$312.0M
Operating Profit$-29.0M$-31.0M$-49.0M$-22.0M$150.0M
Net Profit$-28.0M$-30.0M$-46.0M$-18.0M$163.0M
EPS$-0.75$-0.74$-0.91$-0.30$2.04
Op Margin-15417.5%-46819.9%—-51.4%48.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$69.0M$62.0M$82.0M$119.0M$826.0M
Total Liabilities$6.0M$7.0M$12.0M$34.0M$421.0M
Cash$53.0M$43.0M$44.0M$41.0M$146.0M
Borrowings$1.0M$1.0M$1.0M$1.0M$149.0M

Latest News

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates Zacks · Jul 9, 2026 Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue? Zacks · Jul 8, 2026 RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating MT Newswires · Jul 7, 2026 CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer MT Newswires · Jul 2, 2026 CRMD's Growth Story Expands Beyond DefenCath Into New Trends Zacks · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-21.0M$-24.0M$-38.0M$-51.0M$175.0M
Investing Cash Flow$-11.0M$-4.0M$-17.0M$21.0M$-311.0M
Financing Cash Flow$0$0$0$7.0M$-2.0M
Net Cash Flow$11.0M$-10.0M$0$-3.0M$105.0M
Free Cash Flow$-23.0M$-25.0M$-39.0M$-51.0M$173.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.39
EV / EBITDA2.86
FCF Yield29.26%
Quick Ratio2.74
Interest Coverage50.00
Return 1Y-30.72%
Return 3Y110.73%
Return 5Y24.92%

Ownership

Insiders Held7.53%
Institutions Held54.74%
Institutions Float Held59.19%
Institutional HolderSharesReport Date
Deep Track Capital, Lp6,274,0762026-03-31
Blackrock Inc.5,967,5752026-03-31
Vanguard Capital Management LLC3,129,6562026-03-31
State Street Corporation2,191,8432026-03-31
Royce & Associates LP1,887,5322026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABUS $4.41 +0.00% -25.41 $871.14M 0.00%
BCAX $27.81 +2.92% -7.37 $1.52B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%
NBTXNanobiotix S.A. $40.18 +1.21% -68.71 $2.03B 0.00%

About CRMD

CRMD is led by CEO Joseph Todisco, employs 64 people, headquartered in US, publicly traded since 2010.

CRMD stock trades at $7.33 with a market capitalization of $574.66M. The stock is valued at a price-to-earnings (P/E) ratio of 3.94, price-to-book of 1.53, price-to-sales of 1.68. Over the past 52 weeks the stock has ranged between $6.13 and $17.43, and currently trades 57.9% below its 52-week high.

On profitability, CRMD generates a return on equity (ROE) of 65.59% — well above the market average, a sign of a high-quality business, return on capital employed of 37.04%, an operating margin of 48.41%, a net profit margin of 45.25%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides